Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …

Background Cardiac muscle hypercontractility is a key pathophysiological abnormality in
hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow …

Background Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is
recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable …

Pacemaker treatment for bradyarrhythmia was first approved for national health insurance
coverage in Japan in 1974, and its use rapidly became widespread thereafter …

Hypertrophic cardiomyopathy (HCM) is a common, serious, genetic heart disorder. Rare
pathogenic variants in sarcomere genes cause HCM, but with unexplained phenotypic …

The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …

This international multidisciplinary document intends to provide clinicians with evidence-
based practical patient-centered recommendations for evaluating patients and decedents …